抗凝治疗对肺栓塞高危因素的AECOPD的临床价值

目的探讨抗凝治疗对具有肺栓塞(PE)高危因素的慢性阻塞性肺疾病急性加重(AECOPD)的临床价值。方法将36例D-二聚体阳性的重度AECOPD患者随机分为抗凝组(A组)和非抗凝组,抗凝组在常规治疗基础上,使用低分子肝素5000μ皮下注射,q12h*7天,观察抗凝组和非抗凝组治疗前后临床症状,D-二聚体,动脉血氧分压的变化。结果抗凝组与非抗凝组比较临床症状改善,动脉血氧分压回升,D-二聚体水平降低等比较,差异有统计学意义(P<0.05)。结论具有肺栓塞高危因素,D-二聚体阳性的重度AECOPD患者,应常规给以抗凝治疗。

Clinical value of anti-coagulation in the treatment of high risk factors of pulmonary embolism in AECOPD patients

Objective To investigate the clinical value of the anti-coagulation in the treatment ot patients with acute exacerbatmn of chronic obstructive pulmonary disease （AECOPD） who had high risk factors of pulmonary embolism （ PE ）. Methods 36 patients with severe AECOPD with a positive D-dimmer assay were randomly into the anti-coagulation group and the non-anti-coagulation group. All pa- tients were given normal treatment, and the anti-coagulation group was subcutaneously injected 5000 ~L of low molecular heparin once every 12 hours for 7 days. The clinical symptoms were analyzed and compared between the two groups before and after the treatment. Results The improvement of clinical symptoms was more pronounced in the anti-coagulation group than in the non-anti-coagulation group. Conclu- sion Patients with AECOPD who have the risk factors of pulmonary embolism should immediately be given conventional anti-coagulation treatment.